ES2570769T3 - Triazolopiridinas como inhibidores fosfodiesterasa para el tratamiento de enfermedades dérmicas - Google Patents

Triazolopiridinas como inhibidores fosfodiesterasa para el tratamiento de enfermedades dérmicas

Info

Publication number
ES2570769T3
ES2570769T3 ES09795687T ES09795687T ES2570769T3 ES 2570769 T3 ES2570769 T3 ES 2570769T3 ES 09795687 T ES09795687 T ES 09795687T ES 09795687 T ES09795687 T ES 09795687T ES 2570769 T3 ES2570769 T3 ES 2570769T3
Authority
ES
Spain
Prior art keywords
alkyl
cycloalkyl
nr7r8
aryl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09795687T
Other languages
English (en)
Inventor
Simon Feldbæk Nielsen
Thomas Vifian
Anne Marie Horneman
Jesper Færgemann Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Application granted granted Critical
Publication of ES2570769T3 publication Critical patent/ES2570769T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de la fórmula general I, **Fórmula** en donde R1 es alcoxi C1-6, tal como metoxi, mono-, di- o trifluorometoxi, halógeno, o hidroxi; R2 es alquilo, cicloalquilo, alquilcicloalquilo, o cicloalquilo(C(O)NR7R8), cada uno de los cuáles se sustituye opcionalmente con uno o más sustituyentes seleccionados de R4; R3 es hidrógeno, halógeno, arilo, heteroarilo, hidroxi, alquilo, cicloalquilo, heterocicloalquilo, alcoxi, oxo, ciano, amino, aminoalquilo, alquilamino o dialquilamino; R4 es hidrógeno, halógeno, hidroxi, oxo, ciano, carboxi, o trihalometilo, o R4 es NR5R6,-C(O)NR7R8 ,-C(O)R7,-COOR7,-NR5C(O)NR7R8,-OC(O)NR7R8,-OC(O)R3, NC(O)R7,-OR7,-NC(O)OR3,-NSO2R7,-SO2NR7R8, o-SO2R,R8, alquilo, cicloalquilo, alquenilo, alquinilo, arilo, heteroarilo, cicloalquilalquilo, cicloalquilalquenilo, cicloalquilalquinilo, cicloalquenilalquilo, cicloalquenilalquenilo, cicloalquenilalquinilo, heterocicloalquilo, heterocicloalquilalquilo, heterocicloalquenilo, heterocicloalquenilalquilo, heterocicloalquenilalquenilo, heterocicloalquenilalquinilo, arilalquilo, arilalquenilo, arilalquinilo, heteroarilalquilo, heteroarilalquenilo, heteroarilalquinilo, alcoxi, cicloalquiloxi, alquiltio, cicloalquiltio, sulfamoilo, sulfinamoilo, alquilamino o cicloalquilamino, cada uno de los cuáles se sustituye opcionalmente con uno o más sustituyentes seleccionados de R9; R5 y R6 cada uno representa independientemente hidrógeno, alquilo, alquenilo, cicloalquilo, heterocicloalquilo,-C(O)alquilo,-C(O)Oalquilo,-C(O)cicloalquilo,-C(O)N-alquilo, carboxialquilo,-C(O)alquil-C(O)OH,-C(O)alquil-C(O)N-alquilo,-C(O)Narilo,-S(O)2alquilo,-S(O)alquilo,-S(O)2arilo,-S(O)2N-alquilo,-S(O)arilo, arilo, heteroaril alquilarilo o alquilheteroarilo, cada uno de los cuáles se sustituye opcionalmente con hidroxi o una o más halógenos, o R5 y R6 juntos con el átomo de nitrógeno al que se unen forman un anillo heterocicloalquilo, en donde dicho anillo se sustituye opcionalmente con uno o más grupos alquilo; R7 y R8 cada uno representa independientemente hidrógeno, alquilo, cicloalquilo, alquenilo, heteroarilo, heterocicloalquilo, carboxialquilo, carbamoilalquilo, alquiloxialquilo, alqueniloxialquilo, arilo, arilalquilo, alquilarilo, heteroarilo, heteroarilalquilo, o alquilheteroarilo, cada uno de los cuáles se sustituye opcionalmente con uno o más sustituyentes seleccionados del grupo que consiste de hidroxi, halógeno, oxo, ciano, alquilo, cicloalquilo, alquenilo, alcoxi, arilo, heteroarilo, heterocicloalquilo,-S(O)2-alquilo,-S(O)2-N11R12,-NC(O)-alquilo,-C(O)N-alquilo,-NC(O)O-35 alquilo,-OC(O)N-alquilo,-NC(O)N11R12,-N11SO2-alquilo,-S(O)-alquilo, o R7 y R8 juntos con el átomo de nitrógeno al que se unen forman un anillo heterocicloalquilo, en donde dicho anillo se sustituye opcionalmente con uno o más grupos alquilo; R9 es hidrógeno, halógeno, hidroxi, alcoxi, carboxi o trihalometilo; X y Y son C y N o N y C, respectivamente; A es arilo, cicloalquilo, cicloalquenilo, heteroarilo, heterocicloalquilo o heterocicloalquenilo, cada uno se sustituye opcionalmente con uno o más sustituyentes seleccionados del grupo que consiste de R10; R10 es hidrógeno, ciano, halógeno, hidroxi, u oxo, o R10 es alquilo, cicloalquilo, alquenilo, alquinilo, arilo, heteroarilo, cicloalquilalquilo, cicloalquilalquenilo, cicloalquilalquinilo, cicloalquenilalquilo, cicloalquenilalquenilo, cicloalquenilalquinilo, heterocicloalquilo, heterocicloalquenilo, heterocicloalquenilalquilo, heterocicloalquenilalquenilo, heterocicloalquenilalquinilo, arilalquilo, arilalquenilo, arilalquinilo, heteroarilalquilo, heteroarilalquenilo, heteroarilalquinilo, alcoxi, cicloalquiloxi, alquiltio, cicloalquiltio,-S(O)alquilo,-S(O)2-alquilo, sulfamoilo, sulfinamoilo,-C(O)OR3,-C(O)R3,-NR5R6,-alquilo(NR5R6),-cicloalquilo(NR5R6),-cicloalquilalquilo(NR5R6),-alquilcicloalquilo(NR5R6),-C(O)NR7R8,-alquilo(C(O)NR7R8-cicloalquilo(C(O)NR7R8),-cicloalquilalquilo(C(O)NR7R8) o-alquilcicloalquilo(C(O)NR7R8), cada uno de los cuáles se sustituye opcionalmente con uno o más sustituyentes seleccionados de R4; 11 y R12 cada uno representa independientemente hidrógeno o alquilo; y sales farmacéuticamente aceptables, hidratos, óxidos N o solvatos de los mismos.
ES09795687T 2008-12-19 2009-12-18 Triazolopiridinas como inhibidores fosfodiesterasa para el tratamiento de enfermedades dérmicas Active ES2570769T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13944508P 2008-12-19 2008-12-19
PCT/DK2009/000262 WO2010069322A1 (en) 2008-12-19 2009-12-18 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases

Publications (1)

Publication Number Publication Date
ES2570769T3 true ES2570769T3 (es) 2016-05-20

Family

ID=41693461

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09795687T Active ES2570769T3 (es) 2008-12-19 2009-12-18 Triazolopiridinas como inhibidores fosfodiesterasa para el tratamiento de enfermedades dérmicas

Country Status (25)

Country Link
US (1) US8952162B2 (es)
EP (1) EP2379548B1 (es)
JP (2) JP5743901B2 (es)
KR (1) KR20110094355A (es)
CN (1) CN102317287B (es)
AU (1) AU2009328752B2 (es)
BR (1) BRPI0922452A2 (es)
CA (1) CA2747022A1 (es)
CY (1) CY1117562T1 (es)
DK (1) DK2379548T3 (es)
ES (1) ES2570769T3 (es)
HK (1) HK1165791A1 (es)
HR (1) HRP20160488T1 (es)
HU (1) HUE027770T2 (es)
IL (1) IL213570A (es)
MX (1) MX2011006428A (es)
NO (1) NO20110871A1 (es)
NZ (1) NZ593595A (es)
PL (1) PL2379548T3 (es)
RS (1) RS54752B1 (es)
RU (1) RU2544011C2 (es)
SG (1) SG172206A1 (es)
SI (1) SI2379548T1 (es)
WO (1) WO2010069322A1 (es)
ZA (1) ZA201104422B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
ME01858B (me) 2009-07-17 2014-12-20 Japan Tobacco Inc Jedinjenje triazolopiridina i njegovo dejstvo kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
BR112012015449B1 (pt) 2009-12-22 2021-09-28 Leo Pharma A/S Suspensão de monoidrato de calcipotriol, e, processo para preparar nanocristais de monoidrato de calcipotriol
CA2785251A1 (en) 2009-12-22 2011-06-30 Leo Pharma A/S Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
CA2785254A1 (en) 2009-12-22 2011-06-30 Leo Pharma A/S Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
US9387195B2 (en) 2011-03-07 2016-07-12 Celgene Corporation Methods for treating diseases using isoindoline compounds
US8940761B2 (en) 2011-12-21 2015-01-27 Leo Pharma A/S [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors
EP2925364A1 (en) * 2012-11-30 2015-10-07 Leo Pharma A/S A method of inhibiting the expression of il-22 in activated t-cells
WO2014206903A1 (en) 2013-06-25 2014-12-31 Leo Pharma A/S METHODS FOR THE PREPARATION OF SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIDINES
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
EP3724196B9 (en) 2017-12-15 2023-03-22 UNION therapeutics A/S Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
AR114977A1 (es) * 2018-06-27 2020-11-11 Meiji Seika Pharma Co Ltd Cristales de derivado de benzoxazol
JP2021155336A (ja) * 2018-06-27 2021-10-07 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｐｄｅ４阻害剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0771794T3 (da) 1995-05-19 2006-09-11 Kyowa Hakko Kogyo Kk Oxygenholdige heterocykliske forbindelser
CA2272327A1 (en) 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Oxygen-containing heterocyclic compounds
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
WO2006095666A1 (ja) * 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2007091597A (ja) 2005-09-27 2007-04-12 Kyorin Pharmaceut Co Ltd ピラゾロピリジン−４−イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤
US20090196284A1 (en) * 2006-06-28 2009-08-06 Nokia Siemens Networks Gmbh & Co.Kg Method for Providing an Emergency Call Service for VoIP Subscribers
AU2007272009A1 (en) * 2006-07-12 2008-01-17 Syngenta Limited Triazolopyridine derivatives as herbicides
JP2008024599A (ja) * 2006-07-18 2008-02-07 Kyorin Pharmaceut Co Ltd ピリダジノン誘導体、それらを有効成分とするｐｄｅ阻害剤及び医薬
JP2008069144A (ja) 2006-08-17 2008-03-27 Kyorin Pharmaceut Co Ltd ピラゾロン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
CN101679428A (zh) 2007-04-16 2010-03-24 利奥制药有限公司 用于治疗皮肤疾病的作为磷酸二酯酶抑制剂的三唑并吡啶类
US20100130738A1 (en) 2007-06-19 2010-05-27 Yasushi Kohno Pyrazolone derivative and pde inhibitor containing the same as active ingredient
JPWO2008156094A1 (ja) * 2007-06-19 2010-08-26 杏林製薬株式会社 ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
JP2009040711A (ja) 2007-08-08 2009-02-26 Kyorin Pharmaceut Co Ltd カルボスティリル誘導体及びそれらを有効成分とするｐｄｅ阻害剤
JPWO2010035745A1 (ja) 2008-09-25 2012-02-23 杏林製薬株式会社 ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤
TW201020233A (en) 2008-10-09 2010-06-01 Kyorin Seiyaku Kk Isoquinoline derivative, and pde inhibitor comprising same as active ingredient

Also Published As

Publication number Publication date
SI2379548T1 (sl) 2016-06-30
JP2012512192A (ja) 2012-05-31
WO2010069322A1 (en) 2010-06-24
EP2379548A1 (en) 2011-10-26
ZA201104422B (en) 2012-09-26
CY1117562T1 (el) 2017-04-26
JP5743901B2 (ja) 2015-07-01
RS54752B1 (sr) 2016-10-31
PL2379548T3 (pl) 2016-08-31
SG172206A1 (en) 2011-07-28
US8952162B2 (en) 2015-02-10
CN102317287A (zh) 2012-01-11
HUE027770T2 (en) 2016-11-28
CA2747022A1 (en) 2010-06-24
BRPI0922452A2 (pt) 2015-12-15
NO20110871A1 (no) 2011-09-19
IL213570A0 (en) 2011-07-31
DK2379548T3 (en) 2016-05-17
MX2011006428A (es) 2011-07-28
AU2009328752B2 (en) 2015-07-16
RU2544011C2 (ru) 2015-03-10
EP2379548B1 (en) 2016-03-09
KR20110094355A (ko) 2011-08-23
CN102317287B (zh) 2014-10-08
NZ593595A (en) 2013-07-26
US20120028974A1 (en) 2012-02-02
JP2015096535A (ja) 2015-05-21
HRP20160488T1 (hr) 2016-06-17
AU2009328752A1 (en) 2011-07-07
IL213570A (en) 2015-10-29
HK1165791A1 (en) 2012-10-12

Similar Documents

Publication Publication Date Title
ES2570769T3 (es) Triazolopiridinas como inhibidores fosfodiesterasa para el tratamiento de enfermedades dérmicas
CO5690643A2 (es) Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos
CY1118448T1 (el) Παραγωγο δικυκλοανιλινης
EA200901622A1 (ru) Соединения пиперазина с гербицидным действием
NZ532494A (en) Dibenzylamine compound and medicinal use thereof
RS53670B1 (en) TRIAZOLOPIRIMIDINI
AR051514A1 (es) Derivados de pirido[2, 1 - a]isoquinolina sustituidos como inhibidores de dpp-iv; un proceso para su elaboracion; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de distintos tipos de diabetes y de intolerancia a la glucosa.
EP1867331A4 (en) TRIAZOL DERIVATIVE AND ITS USE
WO2005037783A3 (fr) Composes tricycliques comme inhibiteurs de transport de glycine
AR045219A1 (es) Aminas ciclicas inhibidoras de base - 1 que poseen un sustiuyente heterociclico
AR045260A1 (es) Compuestos que contienen imidazo-oxima sustituidos
TW200800949A (en) Macrocylic inhibitors of hepatitis C virus
AR074435A1 (es) Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer.
YU41284A (en) Process for making antibacterial azole compounds
DE60318583D1 (de) N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung
AR079250A1 (es) Derivados de pirazolo[1,5-a]piridina utiles en el tratamiento de enfermedades del snc y canceres, composiciones farmaceuticas que los contienen e intermediario de sintesis.
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
AR066605A1 (es) Derivados de heteroarilamida pirimidona
AR079662A1 (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
NZ596653A (en) Total synthesis of salinosporamide a and analogs thereof
CO5660271A2 (es) Preparacion de peptidos de somatostatina
PE20061489A1 (es) Derivados de pirroliltriazina y procedimiento de preparacion
AR103582A1 (es) Ciclopropabenzofuranil-piridopirazindionas
WO2007003528A3 (en) Metallocene compounds